The study investigators measured urinary and plasma GDF15 in 81 patients with primary aldosteronism and 41 control subjects. Urinary GDF15 was approximately threefold higher in the PA group, while plasma GDF15 was reported as 1.6-fold higher compared with controls. After clinical treatment of PA, both urinary and plasma GDF15 values returned toward control levels, the authors reported. Urinary GDF15 correlated with urinary aldosterone (rho = 0.35, p < 0.01), as well as with age and BMI in this cohort. The preprint notes no correlation between urinary GDF15 and plasma potassium in the human samples.
These human observations anchor the hypothesis that systemic mineralocorticoid excess triggers a renal or systemic response involving GDF15. The cohort sizes (81 PA, 41 controls) were provided in the abstract; the preprint states that samples derived from two centers. The source did not report detailed treatment regimens or patient subgroup breakdowns in the abstract; readers should consult the full preprint for demographic and protocol granularity.
The experimental arm used a murine model of chronic mineralocorticoid excess, driven by DOCP administration, to test whether GDF15 affects potassium homeostasis. Wild-type mice treated with DOCP developed hypokalemia; the preprint provides plasma potassium values (3.5 ± 0.1 mM in DOCP-treated WT versus 4.3 ± 0.1 mM in controls, p < 0.01). In mice genetically deficient for GDF15 (GDF15KO), the DOCP-induced drop in plasma K was more severe than in WT animals, indicating a functional, protective role for GDF15 against aldosterone-mediated potassium loss.
The authors reported a twofold rise in 24-hour urinary GDF15 in WT mice after DOCP exposure and documented increased GDF15 expression in the collecting duct. The preprint did not include DOCP dosing details in the abstract; specific dosing and administration schedules appear in the full methods but are not reproduced here. The key experimental message is clear: absence of GDF15 impaired the kidney’s ability to blunt mineralocorticoid-driven hypokalemia in this model.
Tissue-level analyses linked the biochemical phenotype to structural and transcriptional changes in the distal nephron. In WT mice, chronic mineralocorticoid exposure increased GDF15 expression in the collecting duct and coincided with an increase in intercalated cell type A (ICA) number. By contrast, GDF15KO mice failed to show this ICA expansion after DOCP, the authors observed.
The preprint includes transcriptomic analysis of collecting-duct cell populations. Authors described an inverted transcriptional response to chronic mineralocorticoid exposure in ICA and principal cells depending on genotype. That phrasing indicates genotype-specific patterns of gene regulation rather than identical shifts across WT and KO animals. The study team proposes that GDF15-dependent ICA proliferation could enhance potassium reabsorption in the collecting duct, attenuating net K loss under high-aldosterone conditions. The abstract does not list specific transporters or individual differentially expressed genes; readers should refer to the supplementary material or the full manuscript for gene-level data and pathway analyses.
The manuscript is a preprint and has not been peer reviewed, a fact the authors explicitly state. The abstract provides cohort sizes and key outcomes but does not reproduce full experimental parameters in this summary: DOCP dosing, detailed patient treatment regimens, and the complete transcriptomic gene lists are not presented in the abstract. The causal chain from GDF15 expression to functional increases in K reabsorption rests on associations of ICA number and transcriptional shifts; direct transport measurements or single-protein functional validation are not detailed in the abstract.
Unanswered questions remain. The preprint does not specify whether urinary or plasma GDF15 measurements have prognostic value for which PA patients will develop hypokalemia. Mechanistic steps connecting specific transcriptional changes to altered transport activity in ICA or principal cells require further functional validation. Finally, translation from the mouse DOCP model to human PA pathophysiology will require replication in broader patient cohorts and peer-reviewed confirmation.
The authors acknowledge funding from Agence Nationale de la Recherche (ANR-21-CE14-0040-01). No competing interests were declared in the preprint. For protocol details, complete gene lists, and DOCP regimens, consult the full preprint and supplementary files linked by the authors.